2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Omics Technologies, Bioinformatics, Computational Biology, Treatment Considerations, Drug Development, Biological Therapies, Transplantation, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Clinical Practice (Health Services and Quality), Diseases, Bone Marrow Failure Syndromes, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, CLL, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Animal Model
PAPER

6016 Targeting the corneal mechano-vicious cycle: Artesunate precisely inhibits pathogenic ITGA11⁺ fibroblasts to treat ocular chronic graft-versus-host disease

Xianjing Cheng, PhD, Longfei Yang2, Xinwen Zhang3, Huhai Yuan4, Rui Ji, PhD5, Yibo Wang6, Haoqi Li7, Xiaoli Liang8, Duo Li9, Ruihao Huang10, Yidan Ye11, Renrui Liu12, Rui Yin13, Wei Fan14, Changzheng Li15, Xiaoqi Wang, MD, PhD16, Xi Zhang, MD17
1 Xinqiao Hospital Army Medical University, Chongqing, China
2 Xinqiao Hospital Army Medical University, Chongqing, China
3 Xinqiao Hospital Army Medical University, Chongqing, China
4 Xinqiao Hospital Army Medical University, Chongqing, China
5 Xinqiao Hospital Army Medical University, Chongqing, China
6 Xinqiao Hospital Army Medical University, Chongqing, China
7 Guangzhou Medical University, Guangzhou, China
8 Xinqiao Hospital Army Medical University, Chongqing, China
9 Xinqiao Hospital Army Medical University, Chongqing, China
10 Xinqiao Hospital Army Medical University, Chongqing, China
11 Xinqiao Hospital Army Medical University, Chongqing, China
12 Xinqiao Hospital Army Medical University, Chongqing, China
13 Xinqiao Hospital Army Medical University, Chongqing, China
14 Xinqiao Hospital Army Medical University, Chongqing, China
15 Xinqiao Hospital Army Medical University, Chongqing, China
16 Xinqiao Hospital Army Medical University, Chongqing, China
17 Xinqiao Hospital Army Medical University, Chongqing, China

Introduction

Ocular chronic graft-versus-host disease (ocGVHD) affects more than 50% of allogeneic hematopoietic stem cell transplant recipients, frequently leading to severe corneal damage and vision loss. This disease remains largely refractory to conventional immunosuppressive therapies, suggesting the involvement of an undefined pathogenic mechanism. Here, we identify a “mechano-vicious cycle” driven by activated fibroblasts as a core mediator of treatment resistance. Through virtual screening, we identify artesunate (ART) as a precision therapeutic agent that disrupts this cycle.

Methods

We integrated clinical cohort data with tear proteomics (n=124), machine learning, and in vivo confocal microscopy (IVCM). Multi-omics profiling included single-cell (scRNA-seq and scATAC-seq) and spatial transcriptomics, complemented by nanoindentation and a fibroblast-specific conditional Itga11 knockout mouse model (Col1a2-CreERT2; Itga11^(fl/fl)). In vitro, stiffness-tunable hydrogels (2–64 kPa) were used to recapitulate the fibrotic corneal microenvironment. Virtual screening of natural compounds was performed by cross-referencing the humanized PDX mouse corneal transcriptome with the Connectivity Map (CMap) database. Molecular targets were validated using DARTS, CETSA, and SPR. A multicenter, prospective, single-arm clinical trial evaluated the efficacy and safety of ART in patients with refractory ocGVHD(Registration Number: ChiCTR2500113111).

Results

The IVCM-based corneal stromal cell activation score strongly correlated with disease severity (P<0.001). Tear proteomics revealed significantly upregulated inflammatory cytokines and fibroblast-derived secretory proteins, which strongly correlated with IVCM scores and corneal stiffness. machine learning-based diagnostic model achieved an AUC of 0.83. In mice, corneal fibroblast activation preceded clinical signs and tissue stiffening. Notably, broad-spectrum TGF-βR inhibition reduced fibrosis but caused corneal thinning and delayed wound healing, underscoring the need for precise targeting of pathogenic subsets. Single-cell transcriptomics identified 14 major cell clusters, with sub-clustering of fibroblasts revealing a distinct pathogenic activated population (ITGA11?Col1a1?). This subset expanded markedly in ocGVHD, was characterized by signatures of "collagen biosynthesis," "extracellular matrix organization," and "response to mechanical stimulus," exhibited a YAP/TAZ-driven fibrotic program with increased chromatin accessibility at YAP/TAZ-TEAD motifs, and spatially colocalized with collagen deposits. Fibroblast-specific Itga11 knockout dramatically reversed fibrosis. Mechanistically, pathogenic fibroblasts secreted collagen-crosslinking enzymes (LOX), which stiffened the matrix and upregulated NINJ1 in corneal epithelial cells. On stiff hydrogels (64 kPa), NINJ1 formed oligomeric membrane pores, causing epithelial damage and the release of DAMPs (ATP, IL-1α), which in turn reactivated fibroblasts, thereby establishing a "stromal stiffening–epithelial injury–inflammation–reactivation" mechano-vicious cycle. Virtual screening identified ART, which showed no in vitro toxicity toward primary human fibroblasts or corneal epithelial cells and dose-dependently suppressed the mechano-activated phenotype. In murine (Balb/c→B10.D2) and humanized PDX cGVHD models, ART (eye drops or intraperitoneal injection) significantly restored Schirmer tear secretion, reduced corneal fluorescein staining scores, and decreased corneal collagen deposition and fibroblast activation (all P<0.01). Mechanistically, ART directly bound to and inhibited this mechanosignaling hub (with detailed molecular target characterization currently ongoing). In the clinical trial(n=9), ART improved OSDI and NIH eye scores, increased Schirmer test values, and reduced corneal fluorescein staining scores, with no grade ≥2 adverse events reported.

Conclusions

This study demonstrates that an ITGA11? fibroblast-driven mechano-vicious cycle constitutes the core mechanism underlying immunosuppression-refractory ocGVHD. Artesunate, identified through virtual screening targeting this mechanosignaling hub, safely and effectively breaks this pathological cycle. Spanning mechanistic discovery, target validation, and clinical investigation, this work provides a new precision therapeutic strategy for ocGVHD.

Xianjing Cheng, PhD: No relevant conflicts of interest to declare.